

Special Issue

Viral Diseases and the Existing Comorbidities: An Overview of Disease Development, Progression, and Therapeutics

Message from the Guest Editors

The current global outbreak of SARS-CoV-2 has indicated that the population with pre-existing comorbidities like age, chronic inflammation, hypertension, cardiovascular disease, diabetes, etc., are vulnerable to a much-increased risk of morbidity and mortality viral diseases. This Special issue will focus on discussing the immune response to viral infections and the disease development among patients with pre-existing comorbidities. Moreover, there is a need to explore how the underlying disease etiologies aggravate the disease progression. Hence, it is of paramount importance to analyze the challenges and options associated with the new and repurposed therapies and the scope of prebiotics or probiotics and vaccine development to prevent viral infections in patients with pre-existing comorbidities. As the current pandemic continues to escalate, we hope this special issue offers healthcare providers and researchers a greater and extensive understanding of the effect of pre-existing comorbidities on developing and treating viral infections.

Guest Editors

Dr. Irfan A. Rather
Dr. Suriya Rehman
Dr. Yan Yan HOR
Dr. Lew Lee Ching

Deadline for manuscript submissions

closed (31 December 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/83933

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).